Review Article| Volume 144, ISSUE 3, P631-636, March 2017

Download started.


Oncofertility for women with gynecologic malignancies

  • Jessica L. Chan
    Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cedars-Sinai Medical Center, Los Angeles, CA, United States
    Search for articles by this author
  • Erica T. Wang
    Corresponding author at: 8635 W. Third Street, Suite 160W, Los Angeles, CA 90048, United States.
    Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cedars-Sinai Medical Center, Los Angeles, CA, United States
    Search for articles by this author
Published:December 22, 2016DOI:


      • Oncofertility addresses fertility and reproductive health needs for cancer patients.
      • In women with new diagnoses of gynecologic cancers, strategies for fertility preservation exist.
      • Patients should be informed about assisted reproductive technology options.


      The emerging field of oncofertility addresses fertility and the reproductive health needs for cancer patients, a key topic in cancer survivorship. Given that the standard treatment for gynecologic malignancies involves removal of reproductive organs, pelvic radiation, or chemotherapy, the effect of such treatment on fertility and options for fertility preservation are even more relevant than for other malignancies.
      In young women with new diagnoses of cervical, endometrial, or ovarian cancers, viable strategies for fertility preservation without compromising oncological outcome exist and should be considered. We present here a comprehensive review of the literature as it pertains to gynecologic malignancies on 1) the effects of radiation and chemotherapy on fertility, 2) fertility-sparing surgeries and the role of assisted reproductive technology, and 3) fertility preservation in adolescent girls and women with BRCA germline mutations.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2015.
        CA Cancer J. Clin. 2015; 65: 5-29
        • Howard-Anderson J.
        • et al.
        Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review.
        J. Natl. Cancer Inst. 2012; 104: 386-405
        • Loren A.W.
        • et al.
        Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
        J. Clin. Oncol. 2013; 31: 2500-2510
        • Ogilvy-Stuart A.L.
        • Shalet S.M.
        Effect of radiation on the human reproductive system.
        Environ. Health Perspect. 1993; 101: 109-116
        • Rodriguez-Wallberg K.A.
        • Oktay K.
        Options on fertility preservation in female cancer patients.
        Cancer Treat. Rev. 2012; 38: 354-361
        • Wallace W.H.
        • Thomson A.B.
        • Kelsey T.W.
        The radiosensitivity of the human oocyte.
        Hum. Reprod. 2003; 18: 117-121
        • Chemaitilly W.
        • et al.
        Acute ovarian failure in the childhood cancer survivor study.
        J. Clin. Endocrinol. Metab. 2006; 91: 1723-1728
        • Milgrom S.A.
        • et al.
        Acute effects of pelvic irradiation on the adult uterus revealed by dynamic contrast-enhanced MRI.
        Br. J. Radiol. 2013; 86: 20130334
        • Arrive L.
        • et al.
        Radiation-induced uterine changes: MR imaging.
        Radiology. 1989; 170: 55-58
        • Bath L.E.
        • et al.
        Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement.
        Br. J. Obstet. Gynaecol. 1999; 106: 1265-1272
        • Critchley H.O.
        • et al.
        Abdominal irradiation in childhood; the potential for pregnancy.
        Br. J. Obstet. Gynaecol. 1992; 99: 392-394
        • Signorello L.B.
        • et al.
        Female survivors of childhood cancer: preterm birth and low birth weight among their children.
        J. Natl. Cancer Inst. 2006; 98: 1453-1461
        • Green D.M.
        • et al.
        Pregnancy outcome of female survivors of childhood cancer: a report from the childhood cancer survivor study.
        Am. J. Obstet. Gynecol. 2002; 187: 1070-1080
        • Warne G.L.
        • et al.
        Cyclophosphamide-induced ovarian failure.
        N. Engl. J. Med. 1973; 289: 1159-1162
        • Goldhirsch A.
        • Gelber R.D.
        • Castiglione M.
        The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.
        Ann. Oncol. 1990; 1: 183-188
        • Rodriguez-Wallberg K.A.
        • Oktay K.
        Fertility preservation during cancer treatment: clinical guidelines.
        Cancer Manag. Res. 2014; 6: 105-117
        • Wang T.H.
        • Wang H.S.
        • Soong Y.K.
        Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.
        Cancer. 2000; 88: 2619-2628
        • Yucebilgin M.S.
        • et al.
        Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility.
        Aust. N. Z. J. Obstet. Gynaecol. 2004; 44: 6-9
        • Soleimani R.
        • et al.
        Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise.
        Aging (Albany NY). 2011; 3: 782-793
        • Bines J.
        • Oleske D.M.
        • Cobleigh M.A.
        Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
        J. Clin. Oncol. 1996; 14: 1718-1729
        • Hortobagyi G.N.
        • et al.
        Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.
        NCI Monogr. 1986; : 105-109
        • Morgan S.
        • et al.
        How do chemotherapeutic agents damage the ovary?.
        Hum. Reprod. Update. 2012; 18: 525-535
        • Minton S.E.
        • Munster P.N.
        Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer.
        Cancer Control. 2002; 9: 466-472
        • Yuksel A.
        • et al.
        The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells.
        Hum. Reprod. 2015; 30: 2926-2935
        • Wright J.D.
        • et al.
        Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access.
        Obstet. Gynecol. 2010; 115: 585-590
        • Gien L.T.
        • Covens A.
        Fertility-sparing options for early stage cervical cancer.
        Gynecol. Oncol. 2010; 117: 350-357
        • Xu L.
        • Sun F.Q.
        • Wang Z.H.
        Radical trachelectomy versus radical hysterectomy for the treatment of early cervical cancer: a systematic review.
        Acta Obstet. Gynecol. Scand. 2011; 90: 1200-1209
        • Lanowska M.
        • et al.
        Radical vaginal trachelectomy (RVT) combined with laparoscopic lymphadenectomy: prospective study of 225 patients with early-stage cervical cancer.
        Int. J. Gynecol. Cancer. 2011; 21: 1458-1464
        • Speiser D.
        • et al.
        Fertility outcome after radical vaginal trachelectomy: a prospective study of 212 patients.
        Int. J. Gynecol. Cancer. 2011; 21: 1635-1639
        • Schneider A.
        • et al.
        Clinical recommendation radical trachelectomy for fertility preservation in patients with early-stage cervical cancer.
        Int. J. Gynecol. Cancer. 2012; 22: 659-666
        • Maneo A.
        • et al.
        Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.
        Gynecol. Oncol. 2008; 111: 438-443
        • Salihi R.
        • et al.
        Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.
        Gynecol. Oncol. 2015; 139: 447-451
        • Clough K.B.
        • et al.
        Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases.
        Cancer. 1996; 77: 2638-2645
        • Morice P.
        • et al.
        Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy.
        Hum. Reprod. 1998; 13: 660-663
        • Feeney D.D.
        • et al.
        The fate of the ovaries after radical hysterectomy and ovarian transposition.
        Gynecol. Oncol. 1995; 56: 3-7
        • Ghadjar P.
        • et al.
        Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation.
        Radiat. Oncol. 2015; 10: 50
        • Lim K.
        • et al.
        Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.
        Int. J. Radiat. Oncol. Biol. Phys. 2011; 79: 348-355
        • Georg D.
        • et al.
        Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy.
        Int. J. Radiat. Oncol. Biol. Phys. 2008; 71: 1272-1278
        • Gunderson C.C.
        • et al.
        Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
        Gynecol. Oncol. 2012; 125: 477-482
        • Gallos I.D.
        • et al.
        LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
        Hum. Reprod. 2013; 28: 2966-2971
        • Baker J.
        • et al.
        Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
        Gynecol. Oncol. 2012; 125: 263-270
        • Mazzon I.
        • et al.
        Conservative surgical management of stage IA endometrial carcinoma for fertility preservation.
        Fertil. Steril. 2010; 93: 1286-1289
        • Lee T.S.
        • et al.
        Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study.
        Gynecol. Oncol. 2013; 131: 289-293
        • Wright J.D.
        • et al.
        Utilization and outcomes of ovarian conservation in premenopausal women with endometrial cancer.
        Obstet. Gynecol. 2016; 127: 101-108
        • Suh-Burgmann E.
        Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
        Gynecol. Oncol. 2006; 103: 841-847
        • Helpman L.
        • et al.
        Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors.
        Fertil. Steril. 2015; 104: 138-144
        • Morice P.
        • et al.
        Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors.
        Int. J. Gynecol. Cancer. 2011; 21: 951-963
        • Wright J.D.
        • et al.
        Fertility preservation in young women with epithelial ovarian cancer.
        Cancer. 2009; 115: 4118-4126
        • Fruscio R.
        • et al.
        Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series.
        Ann. Oncol. 2013; 24: 138-144
        • van der Schouw Y.T.
        • et al.
        Age at menopause as a risk factor for cardiovascular mortality.
        Lancet. 1996; 347: 714-718
        • Parker W.H.
        • et al.
        Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.
        Obstet. Gynecol. 2009; 113: 1027-1037
        • Ethics Committee of American Society for Reproductive, M
        Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion.
        Fertil. Steril. 2013; 100: 1224-1231
        • Practice Committees of American Society for Reproductive, M. and T. Society for Assisted Reproductive
        Mature oocyte cryopreservation: a guideline.
        Fertil. Steril. 2013; 99: 37-43
        • Cobo A.
        • et al.
        Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial.
        Hum. Reprod. 2010; 25: 2239-2246
        • Noyes N.
        • Porcu E.
        • Borini A.
        Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies.
        Reprod. BioMed. Online. 2009; 18: 769-776
        • Cakmak H.
        • et al.
        Effective method for emergency fertility preservation: random-start controlled ovarian stimulation.
        Fertil. Steril. 2013;
        • Hermans A.J.
        • et al.
        Diagnosis and treatment of adnexal masses in children and adolescents.
        Obstet. Gynecol. 2015; 125: 611-615
        • Park J.Y.
        • et al.
        Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
        Gynecol. Oncol. 2015; 137: 418-422
        • de La Motte Rouge T.
        • et al.
        Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
        Ann. Oncol. 2008; 19: 1435-1441
        • Practice Committee of American Society for Reproductive, M
        Ovarian tissue cryopreservation: a committee opinion.
        Fertil. Steril. 2014; 101: 1237-1243
        • Klocke S.
        • et al.
        Slow-freezing versus vitrification for human ovarian tissue cryopreservation.
        Arch. Gynecol. Obstet. 2015; 291: 419-426
        • King M.C.
        • et al.
        Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
        Science. 2003; 302: 643-646
        • American College of, O
        • et al.
        ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome.
        Obstet. Gynecol. 2009; 113: 957-966
        • Piek J.M.
        • et al.
        Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.
        J. Pathol. 2001; 195: 451-456
        • Committee on Gynecologic, P
        Committee opinion no. 620: salpingectomy for ovarian cancer prevention.
        Obstet. Gynecol. 2015; 125: 279-281
        • Yoshida K.
        • Miki Y.
        Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
        Cancer Sci. 2004; 95: 866-871
        • Wang E.T.
        • et al.
        BRCA1 germline mutations may be associated with reduced ovarian reserve.
        Fertil. Steril. 2014; 102: 1723-1728
        • Oktay K.
        • et al.
        Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
        J. Clin. Oncol. 2010; 28: 240-244
        • Collins I.M.
        • et al.
        Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
        J. Clin. Oncol. 2013; 31: 3920-3925
        • Shapira M.
        • et al.
        BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
        Fertil. Steril. 2015; 104: 1162-1167